Hims & Hers Faces Class Action Lawsuit Following FTC Misconduct Complaint

Key Facts

In a move reflecting heightened regulatory scrutiny over digital healthcare firms, Hims & Hers Health and certain executives are facing a securities class action lawsuit. This legal action follows a federal complaint filed by the Federal Trade Commission (FTC) accusing the company of serious business misconduct. According to reports, the revelation of these allegations triggered a sharp decline in the company's share price, prompting legal action from investors seeking to recover losses linked to the regulatory fallout.

The lawsuit centers on concerns regarding the company's business practices and the transparency of its disclosures to shareholders, as detailed in the FTC's findings. Per market data, HIMS shares closed at $30.43 on September 22, 2026, having traded between a day low of $29.23 and a high of $31.81. These price levels underscore the market's reaction to the legal headwinds and the potential for increased regulatory penalties and fees.

Looking ahead, investors are closely monitoring further legal developments that could impact the stock's stability at its current level of $30.43 (close of September 22, 2026). With no immediate corporate catalysts in the upcoming calendar, market attention remains fixed on official responses from management or further regulatory updates, amid a broader economic backdrop that includes upcoming US Initial Jobless Claims data.